{"id":"lenalidomide-oral-capsule","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Neutropenia"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Anemia"},{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Constipation"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Neuropathy"},{"rate":"5-15","effect":"Venous thromboembolism"}]},"_chembl":{"chemblId":"CHEMBL848","moleculeType":"Small molecule","molecularWeight":"259.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lenalidomide binds to cereblon (CRBN), a component of an E3 ubiquitin ligase complex, leading to selective degradation of IKZF1 and IKZF3 proteins. This results in enhanced immune cell activation, increased IL-2 and TNF-α production by T cells, and direct anti-proliferative and pro-apoptotic effects on malignant cells. It also has anti-angiogenic properties that inhibit new blood vessel formation in tumors.","oneSentence":"Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activation while inhibiting pro-inflammatory cytokine production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:31.616Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Myelodysplastic syndromes with deletion 5q"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT07095452","phase":"PHASE2, PHASE3","title":"A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"RECRUITING","sponsor":"AbbVie","startDate":"2026-01-08","conditions":"Multiple Myeloma","enrollment":660},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT03173092","phase":"PHASE4","title":"A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2017-11-13","conditions":"Multiple Myeloma","enrollment":141},{"nctId":"NCT05100862","phase":"PHASE3","title":"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"BeiGene","startDate":"2022-03-10","conditions":"Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma","enrollment":780},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT05730036","phase":"PHASE3","title":"A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-09-18","conditions":"Relapsed Refractory Multiple Myeloma (RRMM)","enrollment":410},{"nctId":"NCT04623541","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":195},{"nctId":"NCT05283720","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-06-14","conditions":"Non-Hodgkin Lymphoma","enrollment":496},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT05660967","phase":"PHASE2","title":"Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2023-03-06","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":111},{"nctId":"NCT06508658","phase":"PHASE3","title":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-08-13","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":360},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT00378105","phase":"PHASE1, PHASE2","title":"Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2006-09","conditions":"Multiple Myeloma","enrollment":68},{"nctId":"NCT06892522","phase":"PHASE1, PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-30","conditions":"Multiple Myeloma","enrollment":440},{"nctId":"NCT07297329","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"RECRUITING","sponsor":"Sinocelltech Ltd.","startDate":"2025-12-29","conditions":"Multiple Myeloma (MM)","enrollment":292},{"nctId":"NCT05556616","phase":"PHASE1","title":"A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D LLC","startDate":"2023-01-12","conditions":"Multiple Myeloma","enrollment":15},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT05259839","phase":"PHASE1","title":"A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-10-20","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":283},{"nctId":"NCT04068597","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies","status":"RECRUITING","sponsor":"CellCentric Ltd.","startDate":"2019-08-09","conditions":"Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma","enrollment":250},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT05429268","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2022-12-23","conditions":"Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":82},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT02252172","phase":"PHASE3","title":"Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-02-16","conditions":"Multiple Myeloma","enrollment":737},{"nctId":"NCT05564052","phase":"PHASE2","title":"A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-06","conditions":"Lymphoma, Mantle-Cell","enrollment":36},{"nctId":"NCT04405167","phase":"PHASE1","title":"Tasquinimod for the Treatment of Relapsed or Refractory Myeloma","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT04257448","phase":"PHASE1, PHASE2","title":"Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2020-05-25","conditions":"Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":75},{"nctId":"NCT05145400","phase":"PHASE2","title":"Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-02-18","conditions":"Multiple Myeloma, Cancer","enrollment":50},{"nctId":"NCT07184424","phase":"NA","title":"Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC","status":"COMPLETED","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2023-05-24","conditions":"HCC - Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT06082102","phase":"PHASE3","title":"Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2023-12-19","conditions":"Relapsed/Refractory Marginal Zone Lymphoma","enrollment":324},{"nctId":"NCT01659658","phase":"PHASE3","title":"Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2012-12-26","conditions":"Relapsed or Refractory Systemic Light Chain Amyloidosis","enrollment":177},{"nctId":"NCT05308654","phase":"PHASE1","title":"A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2022-05-17","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":34},{"nctId":"NCT05409066","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-09-20","conditions":"Follicular Lymphoma (FL)","enrollment":549},{"nctId":"NCT06464991","phase":"PHASE3","title":"A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)","status":"RECRUITING","sponsor":"Nanjing IASO Biotechnology Co., Ltd.","startDate":"2024-03-27","conditions":"Multiple Myeloma","enrollment":240},{"nctId":"NCT06087653","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"Starton Therapeutics, Inc","startDate":"2023-10-02","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT02719613","phase":"PHASE2","title":"Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2016-07-15","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT03412565","phase":"PHASE2","title":"A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-26","conditions":"Multiple Myeloma","enrollment":265},{"nctId":"NCT04737889","phase":"PHASE2","title":"Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-01-13","conditions":"Primary Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT03376672","phase":"PHASE2","title":"Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Raija Silvennoinen","startDate":"2018-05-31","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT04717700","phase":"PHASE2","title":"Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ida Bruun Kristensen","startDate":"2021-08-18","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT02924272","phase":"PHASE2","title":"Ixazomib Rollover Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-12-16","conditions":"Multiple Myeloma, Lymphoma, Amyloidosis","enrollment":32},{"nctId":"NCT03031483","phase":"PHASE2","title":"Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2017-04-03","conditions":"Mucosa Associated Lymphoid Tissue (MALT) Lymphoma","enrollment":44},{"nctId":"NCT05669989","phase":"PHASE2","title":"International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Plasma Cell Myeloma","enrollment":70},{"nctId":"NCT04782687","phase":"PHASE2","title":"Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"US Oncology Research","startDate":"2021-09-10","conditions":"Multiple Myeloma, Myeloma Multiple, Kahler Disease","enrollment":73},{"nctId":"NCT05201248","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-03-10","conditions":"B-Cell Non-Hodgkin Lymphoma","enrollment":49},{"nctId":"NCT05665140","phase":"PHASE2, PHASE3","title":"Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"University Hopsital Schleswig Holstein Campus Lübeck","startDate":"2023-02-03","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":100},{"nctId":"NCT03319667","phase":"PHASE3","title":"A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2017-12-07","conditions":"Plasma Cell Myeloma","enrollment":475},{"nctId":"NCT04974216","phase":"PHASE2","title":"Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-12-20","conditions":"DLBCL","enrollment":71},{"nctId":"NCT03000634","phase":"PHASE2","title":"2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2017-04-01","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT01178814","phase":"PHASE2","title":"Revlimid in Transfusion Dependent Patients","status":"COMPLETED","sponsor":"Columbia University","startDate":"2009-06-01","conditions":"Myelodysplastic Syndrome","enrollment":57},{"nctId":"NCT06033820","phase":"PHASE2","title":"Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-10-12","conditions":"Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory","enrollment":20},{"nctId":"NCT06240520","phase":"PHASE1, PHASE2","title":"Optimizing Reversal of HIV Latency With Combination Therapy","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2024-04","conditions":"Hiv","enrollment":49},{"nctId":"NCT03151811","phase":"PHASE3","title":"A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide","status":"TERMINATED","sponsor":"Oncopeptides AB","startDate":"2017-06-12","conditions":"Multiple Myeloma","enrollment":495},{"nctId":"NCT02600897","phase":"PHASE1, PHASE2","title":"A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-24","conditions":"Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma","enrollment":114},{"nctId":"NCT03433001","phase":"","title":"A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-04-02","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":295},{"nctId":"NCT03733691","phase":"PHASE2","title":"Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2019-03-01","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":19},{"nctId":"NCT02685826","phase":"PHASE1, PHASE2","title":"A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-04-25","conditions":"Multiple Myeloma","enrollment":56},{"nctId":"NCT05598580","phase":"PHASE4","title":"Immunomodulators on HIV-1 Reservoir","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2022-11-20","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT01850524","phase":"PHASE3","title":"IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2013-04-29","conditions":"Multiple Myeloma","enrollment":705},{"nctId":"NCT03001804","phase":"","title":"Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-06-30","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT05771883","phase":"PHASE1, PHASE2","title":"A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide","status":"UNKNOWN","sponsor":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc.","startDate":"2023-05","conditions":"B-cell Non-Hodgkin's Lymphoma","enrollment":102},{"nctId":"NCT03003520","phase":"PHASE2","title":"A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-02-28","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":46},{"nctId":"NCT03948035","phase":"PHASE3","title":"Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wuerzburg University Hospital","startDate":"2018-08-28","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":576},{"nctId":"NCT04094142","phase":"PHASE2","title":"Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2019-07-09","conditions":"Non-hodgkin Lymphoma,B Cell","enrollment":66},{"nctId":"NCT05797948","phase":"NA","title":"GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-07-01","conditions":"Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT00783367","phase":"PHASE2","title":"Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2008-07","conditions":"Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma","enrollment":50},{"nctId":"NCT01564537","phase":"PHASE3","title":"A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-08-01","conditions":"Relapsed Multiple Myeloma, Refractory Multiple Myeloma","enrollment":722},{"nctId":"NCT01938001","phase":"PHASE3","title":"Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-11-21","conditions":"Lymphoma, Non-Hodgkin","enrollment":358},{"nctId":"NCT05690191","phase":"","title":"Chidamide in Patients With Recurrent and Refractory Diffuse Large b","status":"ENROLLING_BY_INVITATION","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2021-06-01","conditions":"Diffuse Large B-cell Lymphoma","enrollment":169},{"nctId":"NCT01335399","phase":"PHASE3","title":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-08-04","conditions":"Multiple Myeloma","enrollment":748},{"nctId":"NCT03416374","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-02-18","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":45},{"nctId":"NCT05552937","phase":"PHASE2","title":"Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL","status":"RECRUITING","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","startDate":"2021-09-06","conditions":"DLBCL","enrollment":50},{"nctId":"NCT01547260","phase":"PHASE1, PHASE2","title":"Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer","status":"COMPLETED","sponsor":"Maria Liljefors","startDate":"2009-10","conditions":"Pancreatic Carcinoma Metastatic, Pancreatic Ductal Adenocarcinoma","enrollment":34},{"nctId":"NCT01555281","phase":"PHASE1, PHASE2","title":"Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2012-02-23","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT02272803","phase":"PHASE2","title":"Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-02-20","conditions":"Multiple Myeloma","enrollment":82},{"nctId":"NCT01239797","phase":"PHASE3","title":"Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2011-06-20","conditions":"Lymphoma, Multiple Myeloma","enrollment":646},{"nctId":"NCT05183139","phase":"PHASE4","title":"A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2022-06-30","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT05200312","phase":"PHASE2","title":"A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-02-01","conditions":"Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":36},{"nctId":"NCT02954406","phase":"PHASE1","title":"A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2017-03-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":43},{"nctId":"NCT00774345","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy","status":"COMPLETED","sponsor":"Celgene","startDate":"2009-01-27","conditions":"B-cell Chronic Lymphocytic Leukemia","enrollment":317},{"nctId":"NCT04989140","phase":"PHASE4","title":"Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-07-26","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT01953692","phase":"PHASE1","title":"A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-11-22","conditions":"Myelodysplastic Syndrome, Multiple Myeloma, Hodgkin Lymphoma","enrollment":197},{"nctId":"NCT02579863","phase":"PHASE3","title":"Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-19","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT01891643","phase":"PHASE3","title":"PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2013-09-30","conditions":"Newly Diagnosed, Previously Untreated Multiple Myeloma","enrollment":23},{"nctId":"NCT02128230","phase":"PHASE2","title":"UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2014-06-10","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT00981708","phase":"PHASE1, PHASE2","title":"Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)","status":"COMPLETED","sponsor":"University of Athens","startDate":"2008-02","conditions":"Amyloidosis","enrollment":37},{"nctId":"NCT02036502","phase":"PHASE1","title":"A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-02-14","conditions":"Multiple Myeloma","enrollment":77},{"nctId":"NCT02917941","phase":"PHASE2","title":"A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-11-01","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":34},{"nctId":"NCT00532675","phase":"PHASE1","title":"Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04-22","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT00642954","phase":"PHASE1","title":"Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02-13","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":31},{"nctId":"NCT01542918","phase":"PHASE1","title":"Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma","status":"COMPLETED","sponsor":"James Rubenstein","startDate":"2012-12-17","conditions":"Recurrent/Refractory CNS, Intraocular Lymphoma","enrollment":14},{"nctId":"NCT01615042","phase":"PHASE1","title":"Phase I Study of Lenalidomide in Patients With Acute Leukemia","status":"TERMINATED","sponsor":"Mehrdad Abedi, MD","startDate":"2012-08","conditions":"Acute Leukemia","enrollment":6},{"nctId":"NCT04272775","phase":"PHASE1","title":"A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)","status":"TERMINATED","sponsor":"Takeda","startDate":"2012-06-05","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":14},{"nctId":"NCT03015922","phase":"PHASE1","title":"Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2017-06-05","conditions":"Multiple Myeloma","enrollment":4},{"nctId":"NCT02538965","phase":"PHASE2","title":"A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-11-19","conditions":"Leukemia, Myeloid","enrollment":17},{"nctId":"NCT00975806","phase":"PHASE1, PHASE2","title":"Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma","status":"TERMINATED","sponsor":"Celgene","startDate":"2009-09-01","conditions":"Renal Cell Carcinoma","enrollment":16},{"nctId":"NCT00655668","phase":"PHASE2","title":"A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Celgene","startDate":"2008-03-01","conditions":"T-cell Non-Hodgkin's Lymphoma","enrollment":54},{"nctId":"NCT01197560","phase":"PHASE2, PHASE3","title":"Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Celgene","startDate":"2010-09-02","conditions":"Diffuse Large B-cell Lymphoma","enrollment":111},{"nctId":"NCT00689936","phase":"PHASE3","title":"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2008-08-21","conditions":"Multiple Myeloma","enrollment":1623},{"nctId":"NCT01021423","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).","status":"TERMINATED","sponsor":"Celgene","startDate":"2010-04-01","conditions":"Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Revlimid","placebo"],"phase":"phase_3","status":"active","brandName":"Lenalidomide Oral Capsule","genericName":"Lenalidomide Oral Capsule","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lenalidomide is an immunomodulatory agent that enhances T-cell proliferation and NK cell activation while inhibiting pro-inflammatory cytokine production. Used for Multiple myeloma, Myelodysplastic syndromes with deletion 5q, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}